Micafungin
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Micafungin: From Antifungal Therapy to Urinary Tract Infection
One-Sentence Summary
Micafungin is an echinocandin antifungal established for invasive Candida infections, acting via inhibition of 1,3-β-D-glucan synthase in the fungal cell wall. The TxGNN model predicts it may be effective for Urinary Tract Infection (specifically Candida-associated UTI/candiduria), with no registered clinical trials but 13 supporting publications, including case series and cohort studies, currently identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no UK marketing authorisation on record (drug not currently marketed in the UK) |
| Predicted New Indication | Urinary Tract Infection (Candida-associated) |
| TxGNN Prediction Score | 99.03% |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data from the evidence pack is marked as a data gap. However, based on the supporting literature, micafungin is an echinocandin-class antifungal that inhibits 1,3-β-D-glucan synthase, disrupting fungal cell wall synthesis and exerting fungicidal/fungistatic activity against Candida species.
Echinocandins have traditionally not been recommended for urinary tract infections because of high protein binding and low urinary excretion. However, several of the identified publications report that measured urinary micafungin concentrations are, in practice, sufficient to eradicate candiduria — particularly against fluconazole-resistant strains such as C. krusei, C. glabrata and C. auris, where treatment options are otherwise limited.
This represents a plausible extension of micafungin’s established antifungal mechanism into a related anatomical site (urinary tract) rather than a novel pharmacological application, which strengthens the biological rationale relative to a purely model-driven prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27424599 | 2016 | PK/clinical study | Int J Antimicrob Agents | Urinary micafungin levels sufficient to treat Candida UTI in 6 patients, including fluconazole-resistant cases |
| 39781278 | 2025 | Cohort (susceptibility survey) | Ther Adv Infect Dis | Antifungal susceptibility of Candida species causing UTI and vulvovaginal candidiasis in Vietnam |
| 27587066 | 2016 | Retrospective cohort | Int Urol Nephrol | Micafungin treatment associated with eradication of candiduria among hospitalised patients |
| 29109159 | 2018 | Retrospective cohort | Antimicrob Agents Chemother | Multi-institutional study on management patterns of candiduria, including antifungal overtreatment |
| 35146837 | 2022 | Case series (paediatric) | Pediatr Int | Outcomes of critically ill paediatric ICU patients treated with micafungin for hospital-acquired Candida UTI |
| 31111613 | 2019 | Case report | Transpl Infect Dis | Increased-dose micafungin eradicated chronic C. krusei UTI in a liver/kidney transplant recipient |
| 38827222 | 2024 | Case report | Front Pediatr | Micafungin used to treat C. glabrata urinary infection in a premature neonate |
| 33520520 | 2020 | Case report | Cureus | C. auris UTI in a multimorbid nursing home patient |
| 26937340 | 2016 | Case series | Med Mycol Case Rep | Five cases of candiduria resolved with parenteral micafungin over minimum 6-day courses |
| 38681664 | 2024 | Case report | Med Mycol Case Rep | Unilateral renal fungus ball caused by micafungin-sensitive C. glabrata, treated with antifungal therapy and endoscopic extraction |
UK Market Information
Micafungin currently holds no UK marketing authorisation on record in this evidence pack (market status: Not marketed; 0 authorisations). Any UK development pathway would require a new marketing authorisation application or variation, referencing existing international authorisations and BNF antifungal classification as appropriate.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: This evidence pack flags key warnings, contraindications and mechanism of action as outstanding data gaps (see “To proceed” below) — these must be resolved before any safety assessment can be completed.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic rationale is biologically plausible and supported by a consistent body of case reports, case series and retrospective cohort studies (L3 evidence) showing successful clinical use of micafungin for Candida-associated UTI, particularly in azole-resistant infections. However, no prospective clinical trials exist, and critical safety data (warnings, contraindications) are currently unavailable, which is a blocking gap for full safety evaluation.
To proceed, the following is needed:
- MHRA/manufacturer product label warnings and contraindications (currently marked Blocking data gap)
- Confirmed mechanism of action documentation from DrugBank or SmPC (currently marked High-severity data gap)
- A structured evidence review of the identified literature (formal tiering/relevance assessment — several records remain marked “pending”)
- Consideration of a prospective or registry-based study to generate higher-tier evidence, given the absence of any clinical trials
- Assessment of the UK regulatory pathway, given the drug currently holds no UK marketing authorisation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.